[{"id":"06664c3b-1c85-4e03-93c9-1672ab005d48","acronym":"ORIN1001-C1","url":"https://clinicaltrials.gov/study/NCT05154201","created_at":"2021-12-13T14:12:30.912Z","updated_at":"2024-07-02T16:35:14.161Z","phase":"Phase 1/2","brief_title":"Treatment of Patients With Advanced Solid Tumors With Oral Agent ORIN1001 and in Combination With Standard of Care.","source_id_and_acronym":"NCT05154201 - ORIN1001-C1","lead_sponsor":"Orinove, Inc.","biomarkers":" HER-2 • ER • PGR • ERN1","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER • PGR • ERN1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ORIN1001"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 350","initiation":"Initiation: 07/01/2020","start_date":" 07/01/2020","primary_txt":" Primary completion: 12/30/2024","primary_completion_date":" 12/30/2024","study_txt":" Completion: 12/30/2024","study_completion_date":" 12/30/2024","last_update_posted":"2024-03-19"},{"id":"fd67e9bd-ba6b-4348-a7c5-199d25e09e69","acronym":"","url":"https://clinicaltrials.gov/study/NCT03950570","created_at":"2021-01-18T19:26:42.783Z","updated_at":"2024-07-02T16:35:14.149Z","phase":"Phase 1/2","brief_title":"ORIN1001 in Patients With Advanced Solid Tumors and Relapsed Refractory Metastatic Breast Cancer","source_id_and_acronym":"NCT03950570","lead_sponsor":"Orinove, Inc.","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • albumin-bound paclitaxel • ORIN1001"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 05/25/2019","start_date":" 05/25/2019","primary_txt":" Primary completion: 01/11/2024","primary_completion_date":" 01/11/2024","study_txt":" Completion: 12/30/2024","study_completion_date":" 12/30/2024","last_update_posted":"2024-03-19"}]